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Paul Aveyard and colleagues, in The Lancet, provide 
optimistic news for the management of obesity in 
primary care.1 In this parallel, two-arm, randomised 
trial of screening and a brief intervention for 
obesity in primary care, Aveyard and colleagues 
identiﬁ ed a net weight loss beneﬁ t at 12 months 
from a 30 s active intervention by primary care 
physicians. A striking feature of the study was that 
patients with obesity (body-mass index of at least 
30 kg/m² or at least 25 kg/m² if of Asian ethnicity) 
were invited to participate with no assessment of their 
readiness to change, yet the majority (2263 [83%] of 
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hypothesised advantages of bioresorbable stents 
were not readily detectable: neither vasomotion in 
the stented segment nor angina relief as reported 
by patients were superior to conventional stents. 
An increase in vessel dimensions due to positive 
remodelling as the scaﬀ old degrades could also not be 
demonstrated. This ﬁ nding suggests that in testing 
these scaﬀ olds the well-established endpoints used 
in the evaluation of conventional stents remain the 
benchmark of choice. In this respect, antirestenotic 
eﬃ  cacy, measured using late loss, was inferior to that 
of current generation drug-eluting stents. Moreover, 
the rate of stent thrombosis was signiﬁ cantly higher 
with bioresorbable scaﬀ olds, with an excess of very late 
thrombotic events more than a year after stenting. This 
ﬁ nding adds to concerns in relation to early outcomes 
in previous trials,5,6 and is in keeping with 2 year data 
from another recently reported clinical trial showing 
numerically more stent thrombosis after 1 year with 
bioresorbable scaﬀ olds compared with standard stents.11
Looking forward, two questions need to be answered. 
First, although the clinical outcome data from ABSORB II 
are concerning, it should be noted that the study was not 
powered for clinical endpoints. In particular, it remains to 
be seen whether the adverse safety signal is a real ﬁ nding. 
For this reason, regardless of the follow-up protocol 
originally planned, ongoing large-scale trials with 
bioresorbable scaﬀ olds should schedule additional 
evaluations and report 3 year outcomes for all patients. 
Ultimately, this represents the best chance to assuage 
concerns arising from the observations of Serruys and 
colleagues.10 Second, these data emphasise the need 
to redeﬁ ne the optimal intensity and duration of dual 
antiplatelet therapy in patients treated with these devices. 
For although expectations regarding late performance 
have not been realised to date, the obvious advantage of a 
stent that disappears remains a goal worth pursuing.
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2728 potentially eligible participants) were willing to 
do so, of whom 1882 individuals were eligible to enrol 
in the trial. 940 patients in the active intervention 
group were oﬀ ered a speciﬁ c appointment (made 
before leaving the clinic) to a weight management 
group (12 sessions of 1 h each, once per week) with 
follow-up support and advice, and 942 patients in the 
advice only (control) group were simply advised by the 
primary care doctor that their health would beneﬁ t 
from weight loss. At 12 months, mean weight change 
was 2·43 kg in the advice plus support group compared 
with 1·04 kg in the advice only group, giving an adjusted 
diﬀ erence of 1·43 kg (95% CI 0·89–1·97). The number 
needed to treat to achieve a 5% weight loss (about 
5 kg) at 12 months was 8·8, which is very good for a 
preventive intervention. By comparison, the number 
needed to treat for nicotine replacement therapy with 
respect to 12 month quit rate is about 15² and exercise 
prescriptions for 12 month achievement of physical 
activity guidelines have a number needed to treat of 
about ten.3
It is surprising that this is the ﬁ rst study in primary 
care to investigate a brief intervention for obesity, 
perhaps reﬂ ecting the nihilism about weight loss that 
pervades medical care. A survey of family physicians 
in the USA found that, of ten chronic disorders, 
obesity treatment was regarded as less eﬀ ective than 
all but treatment for drug addiction.4 This ﬁ nding 
supports our experience with physicians who report 
how diﬃ  cult it is for patients to lose weight and 
keep it oﬀ . Physicians might see the task as being too 
complex, lack conﬁ dence in giving nutrition advice,4 
or have become disillusioned with the poor outcomes. 
Clinicians might also fear insulting patients by raising 
the issue of obesity, yet in this study only four (<1%) 
of patients said the interventions were inappropriate 
and unhelpful. Clinicians’ own weight problems might 
also inhibit discussion, but Perri Klass5 suggests that 
health professionals must acknowledge their own 
weight struggles and “do the job eﬀ ectively”. Eﬀ ective 
resources are available in the form of commercial 
weight loss courses, but cost could be a barrier.6
Long-term behaviour change is hard and failed 
attempts at weight loss are ubiquitous. For some 
patients, such as those with a history of weight cycling, 
it could be time to move away from the sisyphean task 
of pursuing weight loss goals and onto achieving other 
valued health goals.7 The eﬀ orts needed to yet again 
break out of the metabolic, physical, psychological, and 
environmental vicious cycles that trap them in the state 
of obesity8,9 might be better directed at healthy eating 
and physical activity with no further weight gain.
However, far from giving up on weight loss entirely, 
Aveyard and colleagues’ results should trigger a 
rethink of the primary care approaches to obesity on 
two counts. First, the positive results of the 30 s active 
intervention signal a need for further such studies so 
that the evidence base for brief interventions for weight 
management matches that for quitting smoking,10 
exercise prescriptions,3 and alcohol problems.11 This brief 
intervention as part of a usual consultation capitalises 
on opportunities within the current systems of primary 
care practice.
The second, bigger rethink is how to work on the 
systems for primary care to achieve both clinical and 
population outcomes. The so-called control group 
in this study was in fact an intervention itself over 
and above current practice. This control intervention 
involved physician training on how to discuss weight 
with patients, addressing of weight bias, weighing of all 
patients, discussion of weight within the consultation, 
giving brief advice, and provision of follow-up phone 
calls and weight measurements. These are all systems 
changes at a practice level and they resulted in a 
12 month weight loss of about 1 kg. Far from being 
trivial, a 1 kg weight loss or even no weight gain 
applied at the population level could help to reduce the 
enormous burden that obesity places on health systems. 
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6 year follow-up supports early autism intervention
There have been few large randomised controlled trials 
of early intervention for children with autism spectrum 
disorder, even fewer with follow-up data, and none 
with such a lengthy follow-up period as that reported 
by Andrew Pickles and colleagues1 in The Lancet. These 
researchers assessed long-term outcomes for children 
who had received a parent-mediated intervention 
versus treatment as usual nearly 6 years earlier. That 
earlier study from 20102 was notable for its rigorous 
methodology.3
The present follow-up study is also worthy of note. 
To appreciate its importance, some background is 
needed on the 2010 study. That study was a large 
randomised controlled trial in which young children 
(aged from 2 years to 4 years and 11 months) were 
assigned to receive treatment as usual (n=75) or 
treatment as usual plus the manual-based Pre-School 
Autism Communication Trial (PACT) programme 
(n=77). The PACT intervention is grounded in 
developmental principles and aims to increase 
parent sensitivity and responsiveness to child 
communication through various strategies such as 
improving parent observation, responsiveness, and 
focused communication. Compared with other early 
intervention approaches for young children with 
autism,4–6 the PACT intervention reported in 2010 was 
a relatively low-intensity programme. Parents received 
2 h clinical sessions every 2 weeks for the ﬁ rst 6 months, 
followed by monthly booster sessions during the ﬁ nal 
6 months. Parents were also asked to implement their 
newly acquired sensitivity and responsivity skills at 
home for 20–30 min each day.
The treatment eﬀ ect was initially viewed as modest,2 
but the updated analysis reported in this follow-up study1 
reveals greater improvements in the intervention group 
than in the treatment-as-usual group. The improvements 
seen from the initial PACT trial are consistent with results 
from other randomised controlled trials of early autism 
interventions.4–6
The follow-up study1 sought to establish the 
long-term durability of these initial treatment gains. 
Follow-up was done at 5·75 years after the trial 
endpoint and included nearly 80% of the original 
sample. The resulting data, which were analysed with 
Although mass, population-wide weight loss is not a 
plausible strategy, prevention of age-related weight 
gain in the adult population is. If primary care systems 
operated in line with the control condition in this study, 
they would contribute to progressively reducing adult 
obesity prevalence.
A primary care system that makes weight a vital 
sign12 by actively monitoring weight in all patients 
and communicating the beneﬁ ts of normal growth 
trajectories for children and no age-related weight gain 
for adults would go a long way to fulﬁ lling its population 
health potential to prevent the weight-related health 
problems that ﬁ ll up its waiting rooms.
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